CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2010; 31(01): 1-3
Oral systemic therapy: Not all "win-win"
Authors
G S Bhattacharyya
Department of Medical Oncology and Clinical Hematology, AMRI Hospitals, Gariahat Road,
Orchid Nursing Home, C I T Road, Scheme VI M, Phoolbagan, Kolkata, India
References
1 Toffoli G, Corona G, Basso B, Boiocchi M. Phar-macokinetic optimization of treatment
with oral etoposide. Clin Pharmacokinet 2004;43:441-66. 2 Davis M. Gender differences in p-glycoprotein: Drug toxicity and response. J Clin
Oncol 2005;23:6439-40. 3 Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: Why are
they important and can they be mini-mized? Crit Rev Oncol Hematol 2005;55:117-42.
4 Largillier R, Etienne-Grimaldi MC, Formento JL, Ciccolini J, Nebbia JF, Ginot A,
et al . Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer
Res 2006;12:5496-502. 5 Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al . Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy
data and novel analyses from two large, randomised, phase III trials. Br J Cancer
2004;90:1190-7. 6 Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3 rd , Carrato A, et al . Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704.
7 Lembersky BC, Wieand HS, Petrelli NJ, O′Connell MJ, Colangelo LH, Smith RE, et al . Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and
leucovorin in stage II and III carci-noma of the colon: Results from National Surgical
Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006;24:2059-64. 8 Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous
palliative chemotherapy. J Clin Oncol 1997;15:110-5. 9 Borner M, Schsffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Peters G, Grynwald
V, Wanders J, de Boer R, Mrtin C, Fumoleau P (2000) A randomized crossover trial comparing
oral UFT Uracil/tegafur)+leucovorin (LV) and intravenous fluorouracil (FU)+LV for
patient preference and pharmacokinetics in advanced colorectal cancer. Proc Am Soc
Clin Oncol 19:741. 10 Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity
of the functional assessment of cancer therapy-colorectal (FACT-C) quality of life
instrument. Qual Life Res 1999;8:181-95.
